NAMs Technology Partn3Ring webinar series: Session 6

Our current Technology Partn3Ring webinar series focuses on new approach methodologies (NAMs) which are replacement technologies for use in assessing chemical or drug toxicity. In the final webinar of the NAMs series, speakers will showcase a genetically engineered lung cancer model, an embryonic zebrafish multi-omics assay for developmental toxicity, lab-grown musculoskeletal tissues and iPSC-derived cardiac and multi-tissue safety screening assays.

Speakers and topics

Hear from technology developers who will showcase their technologies with the potential to replace animal use in regulatory safety testing, and who are all looking to identify new partners for further development, qualification and use. There will be the opportunity to ask questions and connect directly with the developers to explore collaboration opportunities.

Lab grown tissue models of musculoskeletal disease and injury
Andrew Capel (Myomaker Bio)

• Myomaker Bio has developed lab-grown musculoskeletal tissues for preclinical drug development.
• Andrew is looking for end-users to validate the platform against musculoskeletal health, injury, disease and regeneration, plus partners to develop bespoke assays for orphan diseases.

Title TBC
Carlos Lopez-Garcia (Bangor University)

• Carlos's group models lung squamous cell carcinoma by genetically manipulating human bronchial epithelial cells, recapitulating both preinvasive and invasive stages of the disease.
• Carlos is seeking collaborators with organ-on-a-chip platforms, real-time air-liquid interface imaging, or automated media-replacement systems, to monitor invasion and cancer-stromal-immune interactions.

Title TBC
Arantza Muriana (BBD BioPhenix / Biobide)

• Biobide have paired zebrafish embryo assays with multi-omics to predict teratogenicity, generating human-relevant mechanistic data for weight-of-evidence developmental toxicity assessment.
• Arantza is looking for a partner with transcriptomics experience to combine with Biobide's zebrafish capability and validate both reference compounds and the company's own products.

Title TBC
Sanne Holt (Ncardia Services B.V.)

• Ncardia has developed an iPSC-derived, seven-tissue functional safety screening platform and kinetic cardiac profiling, demonstrated through case studies on antibody-drug conjugates and kinase inhibitors.
• Sanne wants to connect with partners to refine the platform and explore how to deploy it widely to support companies' investigational new drug applications.